SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-000119 to NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (NBY)

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: Jan. 4, 2023 · CIK: 0001389545 · Accession: 0000000000-23-000119

AI Filing Summary & Sentiment

File numbers found in text: 333-269083

Date
January 4, 2023
Author
Not clearly detected
Form
UPLOAD
Company
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)

Letter

United States securities and exchange commission logo January 4, 2023 Justin M. Hall, Esq. Chief Executive Officer and General Counsel NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, CA 94608 Re:NovaBay Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 30, 2022 File No. 333-269083 Dear Justin M. Hall: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Abby E. Brown, Esq.

Show Raw Text
United States securities and exchange commission logo
January 4, 2023
Justin M. Hall, Esq.
Chief Executive Officer and General Counsel
NovaBay Pharmaceuticals, Inc.
2000 Powell Street, Suite 1150
Emeryville, CA 94608
Re:NovaBay Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 30, 2022
File No. 333-269083
Dear Justin M. Hall:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Abby E. Brown, Esq.